Citigroup’s Orexigen Therapeutics, Inc. OREX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q2 | – | Sell |
-39,243
| Closed | -$8K | – | 7944 |
|
|
2018
Q1 | $8K | Buy |
39,243
+21,270
| +118% | +$19.6K | ﹤0.01% | 7127 |
|
|
2017
Q4 | $23K | Sell |
17,973
-1,787
| -9% | -$2.91K | ﹤0.01% | 6678 |
|
|
2017
Q3 | $42K | Buy |
19,760
+6,900
| +54% | +$16.8K | ﹤0.01% | 6089 |
|
|
2017
Q2 | $37K | Buy |
12,860
+11,160
| +656% | +$33.5K | ﹤0.01% | 5993 |
|
|
2017
Q1 | $6K | Buy |
1,700
+1,400
| +467% | +$5.53K | ﹤0.01% | 6762 |
|
|
2016
Q4 | $1K | Sell |
300
-2,353
| -89% | -$5.53K | ﹤0.01% | 7160 |
|
|
2016
Q3 | $9K | Sell |
2,653
-1,960
| -42% | -$7.4K | ﹤0.01% | 6609 |
|
|
2016
Q2 | $19K | Sell |
4,613
-6,604
| -59% | -$29.9K | ﹤0.01% | 6214 |
|
|
2016
Q1 | $64K | Buy |
11,217
+5,701
| +103% | +$74K | ﹤0.01% | 5976 |
|
|
2015
Q4 | $95K | Sell |
5,516
-21,172
| -79% | -$505K | ﹤0.01% | 5417 |
|
|
2015
Q3 | $563K | Buy |
26,688
+23,590
| +761% | +$808K | ﹤0.01% | 3633 |
|
|
2015
Q2 | $154K | Buy |
3,098
+104
| +3% | +$6.22K | ﹤0.01% | 4658 |
|
|
2015
Q1 | $235K | Sell |
2,994
-2,980
| -50% | -$185K | ﹤0.01% | 4394 |
|
|
2014
Q4 | $362K | Sell |
5,974
-39,589
| -87% | -$1.99M | ﹤0.01% | 4187 |
|
|
2014
Q3 | $1.94M | Sell |
45,563
-3,312
| -7% | -$178K | ﹤0.01% | 2567 |
|
|
2014
Q2 | $3.02M | Sell |
48,875
-4,019
| -8% | -$234K | ﹤0.01% | 2186 |
|
|
2014
Q1 | $3.44M | Sell |
52,894
-1,847
| -3% | -$125K | ﹤0.01% | 1984 |
|
|
2013
Q4 | $3.08M | Buy |
54,741
+818
| +2% | +$46K | ﹤0.01% | 2207 |
|
|
2013
Q3 | $3.31M | Sell |
53,923
-14,826
| -22% | -$1M | ﹤0.01% | 2101 |
|
|
2013
Q2 | $4.02M | Buy |
+68,749
| New | +$4.23M | ﹤0.01% | 1813 |
|
Other funds holding OREX
Citigroup's OREX Position: Q2 2018 in Review
Citigroup sold out of Orexigen Therapeutics, Inc. (OREX) in Q2 2018, closing a stake of 39,243 shares — an estimated $8K sold.
Citigroup first reported a position in OREX in Q2 2013 and held it in 20 quarters. The position peaked at $4.02M in Q2 2013. 4 funds tracked by Wall St. Rank hold OREX as of Q2 2018.
- Citigroup reported no remaining Orexigen Therapeutics, Inc. position as of Q2 2018 after selling out during the quarter.
- Citigroup sold 39,243 Orexigen Therapeutics, Inc. shares in Q2 2018, an estimated $8K.
- Citigroup first reported a position in Orexigen Therapeutics, Inc. in Q2 2013 and held it in 20 quarters.
- Citigroup's Orexigen Therapeutics, Inc. position peaked at $4.02M in Q2 2013.
- 4 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q2 2018.
Based on Citigroup's 13F filing for Q2 2018, filed 10 Aug 2018.